Books+ Search Results
Resistance to Targeted Therapies in Breast Cancer
Title
Resistance to Targeted Therapies in Breast Cancer [electronic resource] / edited by Jenifer R. Prosperi.
ISBN
9783319701424
Publication
Cham : Springer International Publishing : Imprint: Springer, 2017.
Physical Description
XV, 184 p. 12 illus. in color : 1 online resource.
Local Notes
Access is available to the Yale community.
Access and use
Access restricted by licensing agreement.
Summary
We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy. .
Variant and related titles
Springer ebooks.
Other formats
Printed edition:
Format
Books / Online
Language
English
Added to Catalog
January 11, 2018
Series
Resistance to Targeted Anti-Cancer Therapeutics, 16
Contents
Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target?
Resistance to HER2-targeted therapy
Endocrine Resistance and Breast Cancer Stem Cells – The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes
EGFR Resistance
Targeting FGFR for the treatment of breast cancer
Targeted Therapies in Breast Cancer
Future paradigm of breast cancer resistance and treatment.
Also listed under
SpringerLink (Online service)
Bookmark As
Citation
